Global Perspectives on Acute Lymphocytic Leukemia (ALL) in 2023 and Beyond – Focus on Combination Therapies
Expert perspectives on the latest therapeutic developments, treatment approaches, and implications for clinical decision-making regarding acute lymphocytic leukemia
FACULTY CO-CHAIR
Elias Jabbour, MD
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
FACULTY CO-CHAIR
Gail J. Roboz, MD
Weill Cornell Medicine, New York, NY, USA
FACULTY MEMBERS
Aaron Logan, MD, PhD
University of California, San Francisco, CA, USA
Ibrahim Aldoss, MD
City of Hope, Duarte, CA, USA
Wendy Stock, MD
University of Chicago, Chicago, IL, USA
Andre Schuh, MD, FRCPC
Princess Margaret Cancer Centre, Toronto, ON, Canada
Selina Luger, MD
University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA
Jae Park, MD
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Daniel J. DeAngelo, MD, PhD
Harvard Medical School, Boston, MA, USA
Tobias Menne, MD, PhD
Newcastle upon Tyne Hospitals, United Kingdom
Nicolas Boissel, MD, PhD
Hôpital Saint-Louis, Paris, France
Nicola Gökbuget, MD
University Hospital Frankfurt, Germany
Renato Bassan, MD
Ospedale dell’Angelo and Ospedale SS, Venice, Italy
Shaun Fleming, MBBS (Hons), FRACP, FRCPA
Melbourne Haematology, Richmond, VIC, Australia
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
- Blinatumomab in First Line and Maintenance for ALL
- Backbone Therapies for First-Line AYA ALL
- Backbones for First-Line Ph-Positive ALL
- Backbones for First-Line Ph-Negative ALL – Transplant Ineligible
- Backbones for First-Line Ph-Negative ALL – Transplant Eligible
